Novo Nordisk Past Earnings Performance
Past criteria checks 3/6
Novo Nordisk has been growing earnings at an average annual rate of 19.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 17.8% per year. Novo Nordisk's return on equity is 78.6%, and it has net margins of 35%.
Key information
19.7%
Earnings growth rate
21.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 17.8% |
| Return on equity | 78.6% |
| Net Margin | 35.0% |
| Next Earnings Update | 05 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Novo Nordisk makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 270,583 | 94,721 | 65,722 | 43,300 |
| 30 Jun 24 | 258,003 | 89,898 | 63,205 | 36,246 |
| 31 Mar 24 | 244,243 | 89,276 | 62,528 | 32,907 |
| 31 Dec 23 | 232,261 | 83,683 | 61,598 | 31,029 |
| 30 Sep 23 | 214,490 | 75,312 | 58,063 | 29,308 |
| 30 Jun 23 | 201,325 | 67,239 | 56,597 | 26,813 |
| 31 Mar 23 | 188,290 | 61,129 | 53,014 | 24,809 |
| 31 Dec 22 | 176,954 | 55,525 | 50,684 | 23,287 |
| 30 Sep 22 | 167,195 | 52,825 | 48,415 | 21,021 |
| 30 Jun 22 | 157,251 | 50,539 | 45,949 | 19,640 |
| 31 Mar 22 | 149,027 | 49,344 | 43,023 | 18,461 |
| 31 Dec 21 | 140,800 | 47,757 | 41,058 | 17,199 |
| 30 Sep 21 | 134,605 | 46,183 | 39,200 | 16,273 |
| 30 Jun 21 | 129,910 | 44,362 | 38,237 | 15,932 |
| 31 Mar 21 | 126,875 | 42,864 | 37,557 | 15,279 |
| 31 Dec 20 | 126,946 | 42,138 | 36,886 | 15,462 |
| 30 Sep 20 | 127,225 | 41,537 | 36,693 | 14,913 |
| 30 Jun 20 | 126,575 | 41,433 | 36,283 | 14,603 |
| 31 Mar 20 | 126,605 | 40,403 | 36,490 | 14,869 |
| 31 Dec 19 | 122,021 | 38,951 | 35,830 | 14,220 |
| 30 Sep 19 | 119,336 | 38,731 | 35,056 | 14,352 |
| 30 Jun 19 | 116,821 | 37,574 | 34,346 | 14,395 |
| 31 Mar 19 | 114,192 | 38,322 | 33,855 | 14,134 |
| 31 Dec 18 | 111,831 | 38,628 | 33,313 | 14,805 |
| 30 Sep 18 | 110,091 | 38,384 | 32,729 | 14,244 |
| 30 Jun 18 | 108,943 | 39,117 | 32,062 | 13,928 |
| 31 Mar 18 | 110,174 | 38,725 | 31,739 | 14,046 |
| 31 Dec 17 | 111,696 | 38,130 | 32,124 | 14,014 |
| 30 Sep 17 | 113,276 | 38,576 | 31,786 | 14,501 |
| 30 Jun 17 | 114,199 | 38,609 | 32,268 | 14,631 |
| 31 Mar 17 | 113,020 | 38,626 | 32,390 | 14,548 |
| 31 Dec 16 | 111,780 | 37,925 | 32,339 | 14,563 |
| 30 Sep 16 | 111,084 | 37,484 | 32,467 | 13,884 |
| 30 Jun 16 | 110,339 | 36,064 | 32,495 | 13,715 |
| 31 Mar 16 | 109,939 | 34,439 | 32,817 | 13,419 |
| 31 Dec 15 | 107,927 | 34,860 | 32,169 | 13,608 |
| 30 Sep 15 | 103,636 | 33,131 | 30,712 | 13,616 |
| 30 Jun 15 | 99,093 | 31,248 | 29,578 | 13,381 |
| 31 Mar 15 | 93,663 | 29,899 | 27,870 | 13,421 |
| 31 Dec 14 | 88,806 | 26,481 | 26,760 | 13,762 |
| 30 Sep 14 | 85,919 | 26,005 | 26,571 | 12,863 |
| 30 Jun 14 | 84,181 | 25,920 | 26,153 | 12,604 |
| 31 Mar 14 | 83,932 | 25,660 | 26,448 | 12,244 |
| 31 Dec 13 | 83,572 | 25,184 | 26,888 | 11,733 |
Quality Earnings: NOVA has a high level of non-cash earnings.
Growing Profit Margin: NOVA's current net profit margins (35%) are lower than last year (35.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NOVA's earnings have grown by 19.7% per year over the past 5 years.
Accelerating Growth: NOVA's earnings growth over the past year (25.8%) exceeds its 5-year average (19.7% per year).
Earnings vs Industry: NOVA earnings growth over the past year (25.8%) did not outperform the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: NOVA's Return on Equity (78.6%) is considered outstanding.